FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension

438 Views

Emedinexus 26 September 2024

The U.S. Food and Drug Administration (FDA) has approved aprocitentan (Tryvio) for the treatment of hypertension in adult patients who do not achieve adequate blood pressure control with existing antihypertensive medications.

To comment on this article,
create a free account.

Already registered?

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.